目的：探讨99m Tc-MIBI SPECT/ CT 同机融合亲肿瘤显像预测肺癌化疗疗效的价值。方法43例化疗的肺癌患者分为有效组和无效组，在化疗前行99m Tc-MIBI SPECT/ CT 同机融合亲肿瘤显像，并对所摄取比值行半定量分析，比较两组早期相肿瘤/正常肺组织摄取比值（EUR）和延迟相肿瘤/正常肺组织摄取比值（DUR）、滞留指数（RI）之间的差别。结果化疗有效组的 EUR、DUR、RI 平均值均显著高于无效组（P <0.05）；小细胞肺癌组的 EUR、DUR、RI 平均值均显著高于非小细胞肺癌组（P <0.05）；肺腺癌组的 EUR、DUR、RI 平均值与肺鳞癌组无显著差异（P >0.05）。结论99m Tc-MIBI SPECT/ CT 同机融合亲肿瘤显像在预测肺癌化疗疗效方面具有重要的临床价值。%Objective To explore the value of 99m Tc-MIBI SPECT/ CT pro-tumor fusion image technology in predicting the effects of chemotherapy on lung cancer. Methods Total 43 patients receiving chemotherapy for lung cancer were collected and divided into effective group and ineffective group according to their chemotherapeutic result. Before the chemotherapy,all patients received 99m Tc-MIBISPECT/ CT pro-tumor fusion image examination,the semi-quantitative analysis was made to determine the uptake ratio,and the differences of the early-phase tumor/ normal lung tissue uptake ratio(EUR)and delayed-phase tumor/ normal lung tissue uptake ratio (DUR)as well as the retention index(RI)between the two groups were compared. Results The average values of EUR,DUR and RI of the patients in the effective group were significantly higher than those in the ineffective group(P < 0. 05),the ones in the small cell lung cancer(SCLC)group were significantly higher than those in the non-SCLC group(P < 0. 05),the ones in the lung adenocarcinoma group were no significantly different from those in the squamous cell lung cancer group(P > 0. 05). Conclusion 99m Tc-MIBI SPECT/ CT pro-tumor fusion image technology has important clinical values in predicting the effects of chemotherapy on lung cancer.
展开▼
